諸如諾和諾德 (NVO-US) 出品的 Wegovy 和禮來公司 (LLY-US) 生產的 Zepbound 這類減肥藥開拓了一個市場,分析師預計該市場將在 10 年內成長到 1000 億美元。
In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.
Oppenheimer analyst Jay Olson spent several days last week listening as companies such as Eli Lilly discussed how to improve on blockbusters like Zepbound and Novo Nordisk’s Wegovy.